Articles

Insulin Singled Out in Ambitious Bill By House Democrats to Lower Drug Prices

The bill would mandate that the government negotiate with drug makers about the price of insulin, both in the Medicare program and for the open insurance market. It also includes many other mechanisms intended to lower the price of insulin and other drugs.

FDA experts and Clinicians to Speak at the T1D Exchange Annual Meeting on September 23rd

-T1D Exchange staff On September 23rd, T1D Exchange will hold its annual meeting at the Royal Sonesta in Cambridge, Massachusetts. The theme of this year’s meeting is data–and the  organization’s commitment to use it alongside collaboration to improve outcomes for individuals with type 1 diabetes. In the keynote address, “The Evolution of Real-World Evidence in […]

Children with High Genetic Risk for Type 1 Diabetes Have Distinct Gut Microbiomes When Compared to Those at Lower Risk

An examination of 403 biological samples reveals that some gut bacteria was absent in children at higher risk of developing type 1 diabetes.

CGM News Dominates EASD 2019

CGM News Dominates EASD 2019

5 takeaways from the news coming out of the annual meeting of the European Association for the Study of Diabetes in Barcelona.

The Envision Pro will be factory-calibrated, disposable, and is intended for use by health care professionals.

ollaborations Announced Between Sanofi and Abbott, and Between Novo Nordisk and Medtronic

The two separate collaborations will soon allow the companies to make more readily available blood sugar readings and insulin dosing information across more diabetes devices, apps, and platforms.

Eylea, a Treatment for Diabetic Retinopathy, Now Available in Prefilled Syringes

The drug is just one of two on the market currently approved specifically to treat the diabetes-related eye condition, among other eye ailments.

Connection Found Between HbA1c and Educational Outcomes

Type 1 diabetes is an additional challenge for school-age children, but well-managed type 1 diabetes was not found to be an additional barrier to academic achievement.

ere are Six Recent Moves to Curb Co-Pay Costs for Insulin

Four insurers have introduced a cap on monthly insulin costs, but the federal government’s move to change regulations around high-deductible insurance plans may have the biggest long-term impact.

Implantable CGM Gains Blue Cross Blue Shield Coverage in Two States

Senseonics continues to make inroads in its rollout of the Eversense CGM.